REG - Uniphar PLC - Directorate Change

UnipharAnnouncement

30/01/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240130:nRSd2860Ba&default-theme=true

RNS Number : 2860B  Uniphar PLC  30 January 2024

 

 

Uniphar plc

 

Directorate Change

 

Dublin, London | 30 January 2024: Uniphar plc (the "Company" or "Uniphar"),
an international diversified healthcare services business addressing the needs
of more than 200 multinational pharmaceutical and medical technology
manufacturers, is pleased to announce the appointment of Valerie Sick to its
Board as an independent non-executive Director, with immediate effect.

 

Valerie has over 25 years' senior international experience in private and
publicly listed pharmaceutical and life science companies in Europe. She has
held senior financial and management roles, including managing very diverse
operations from a profitability and value creation point of view. Valerie
currently serves as Chief Financial Officer of bioMerieux Deutschland GmbH and
previous appointments include Director of Finance and Administration of Yves
Rocher GmbH and Global Process Owner - Finance for Celesio AG. She is highly
experienced in strategic change management and integration across multiple
countries and regions to foster growth, with extensive experience in managing
multi-stakeholder engagement and strategic decision-making within complex
regulated environments at global, regional and national levels. Valerie is
fluent in French, German and English and also has a strong interest in climate
friendly business models and long-term sustainable business.

 

Committee Changes

The Company also announces the following non-executive director changes to the
composition of the Committees of the Board with immediate effect:

 

·   Valerie Sick has been appointed to the Nominations, Governance and
Sustainability Committee and the Remuneration Committee.

 

·      Paul Hogan has been appointed as Chair of the Remuneration
Committee following the resignation of Jeffrey Berkowitz.

 

The updated composition of the Committees of the Board will be available on
the Company's website: www.uniphar.com (http://www.uniphar.com) .

 

Maurice Pratt, Chairman of Uniphar plc, commented:

 

"I am delighted to welcome Valerie to the Board of Uniphar where I believe she
will bring extensive commercial and international markets experience and
complement the existing skills and expertise of our Board. I, along with the
rest of the Board, look forward to working with Valerie as Uniphar seeks to
deliver on the significant growth opportunity ahead."

 

Additional Information:

 

Valerie Christine Sick (French citizen, aged 52 years) does not hold any
ordinary shares or options in the Company. The Company confirms that there is
no other information that is required to be disclosed under Schedule 2(g) of
the AIM Rules for Companies.

 

--- ENDS ---

 

 

Contact details

 Uniphar Group                                            Tel: +353 (0) 1 428 7777

 Allan Smylie, Head of Strategy and IR

 Davy (Joint Corporate Broker, Nominated Advisor and      Tel: +353 (0) 1 679 6363

 Euronext Growth Listing Sponsor)

 Daragh O'Reilly

 Niall Gilchrist

 Ivan Murphy

 RBC Capital Markets (Joint Corporate Broker)             Tel: +44 (0) 20 7653 4000

 Jamil Miah

 Rupert Walford

 Stifel Nicolaus Europe Limited (Joint Corporate Broker)  Tel: +44 (0) 20 7710 7600

 Matt Blawat

 Ben Maddison

 Francis North

 Q4 PR                                                    Tel: +353 (0) 1 475 1444

 Iarla Mongey, Public Relations Advisor to Uniphar Group

 

 

 

About Uniphar plc

Headquartered in Dublin, Ireland, the Uniphar Group is an international
diversified healthcare services business servicing the requirements of more
than 200 multinational pharmaceutical and medical technology manufacturers
across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply
Chain & Retail. The Group is active in Europe, North America, APAC and
MENA and delivers to 160+ counties.

 

The Company's vision is to improve patient access to pharmaco-medical products
and treatments by enhancing connectivity between manufacturers and healthcare
stakeholders. Uniphar represents a strong combination of scale, growth, and
profitability.

 

Uniphar Supply Chain & Retail

Uniphar Supply Chain and Retail is the leading pharmaceutical wholesaler in
Ireland with a growing symbol group offering of retail pharmacies. The Group's
strategy for Uniphar Supply Chain and Retail is to grow our wholesale market
share, our symbol group network and our own brand, in-licenced and consumer
products portfolio.

 

Uniphar Medtech

Uniphar Medtech is a leading Pan-European medical device distributor and
solutions partner. The Group's strategy for Uniphar Medtech is to grow our
service offering across Europe and expand our addressable market by serving
new specialities and new manufacturers.

 

Uniphar Pharma

Uniphar Pharma operates a global business with high value services across the
lifecycle of a pharmaceutical product. We enable pharma and biotech companies
to bring innovative medicines to global markets and provide healthcare
professionals with access to medicines they can’t source through traditional
channels. Our strategy is to build a leading platform to provide the
specialist support and expertise needed to improve access to these medicines.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEANFNALLLEFA